Price Disclosure Reductions for 2018 October Cycle
Page last updated: 29 August 2018
This summary only includes medicines taking a price disclosure reduction on 1 October 2018. The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) as amended and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations) in force currently.
The outcomes below show percentage (%) price differences and ex‑manufacturer level prices. They do not include fees and mark-ups. Information about publication of prices including fees and mark-ups is set out below.
Flow-on Reductions for F2 Combination Items
Responsible persons with a brand of an F2 combination item should note that:
- if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 October 2018 if the price of a component ingredient is also reduced and flowing this component price on results in a lower price; or
- if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.
Calculations are currently being completed for flow-on price disclosure reductions to F2 combination items. Outcomes will be communicated to responsible persons with brands of affected drugs early July 2018.
Legal Determination & Next Steps
The weighted average disclosed prices for each brand, including brands with a determination but no reduction, can be found in the legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their April 2018 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable and set out in the table below). Any new brands of an existing pharmaceutical item with a determination in Schedule 1 that listed after 31 March 2018 will also take the reduction on 1 October 2018 under section 99ADHA of the Act.
An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 5 pm AEST on 28 June 2018.
Indicative prices for 1 October 2018 (including price to pharmacy, dispensed price for maximum quantity and price premiums) will be published by early July 2018. Subscribe to PBS News to receive notice when they become available.
Final prices for 1 October 2018 (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from mid-September 2018.
|
Legal Instrument Drug |
Legal Instrument MoA |
Legal Instrument Form |
Average |
WAPD |
WADP - |
April '18 |
Percentage difference between April '18 and October '18 PBS prices (AEMP) |
Calculations based on: |
Unadjusted Price Reduction |
|---|---|---|---|---|---|---|---|---|---|
|
[Average AEMP minus WAPD = WADP]
|
[Difference between October '18 AEMP & WADP = % Difference] |
||||||||
|
Adefovir |
Oral |
Tablet containing adefovir dipivoxil 10 mg |
525.00 |
18.43% |
428.24 |
525.00 |
18.43% |
GWAPD |
10 |
|
Azacitidine |
Injection |
Powder for injection 100 mg |
369.44 |
26.91% |
270.02 |
317.31 |
14.90% |
Does not meet 30 month clock |
10 |
|
Bleomycin |
Injection |
Powder for injection containing bleomycin sulfate 15,000 I.U. |
31.27 |
31.78% |
21.33 |
31.27 |
31.79% |
No originator brand determined |
30 |
|
Bosentan |
Oral |
Tablet 125 mg (as monohydrate) |
2,295.43 |
33.06% |
1,536.56 |
2,295.43 |
33.06% |
Does not meet 30 month clock |
10 |
|
Bosentan |
Oral |
Tablet 62.5 mg (as monohydrate) |
2,295.43 |
33.06% |
1,536.56 |
2,295.43 |
33.06% |
Does not meet 30 month clock |
10 |
|
Capecitabine |
Oral |
Tablet 150 mg |
15.07 |
33.09% |
10.08 |
12.57 |
19.81% |
GWAPD |
10 |
|
Capecitabine |
Oral |
Tablet 500 mg |
93.40 |
33.09% |
62.49 |
77.94 |
19.82% |
GWAPD |
10 |
|
Dorzolamide |
Application to the Eye |
Eye drops 20 mg (as hydrochloride) per mL, 5 mL |
10.11 |
27.75% |
7.30 |
10.11 |
27.79% |
GWAPD |
10 |
|
Dorzolamide with timolol |
Application to the Eye |
Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL |
12.08 |
18.45% |
9.85 |
12.08 |
18.46% |
GWAPD |
10 |
|
Entecavir |
Oral |
Tablet 0.5 mg (as monohydrate) |
306.68 |
31.26% |
210.81 |
234.64 |
10.16% |
Does not meet 30 month clock |
10 |
|
Entecavir |
Oral |
Tablet 1 mg (as monohydrate) |
498.75 |
31.26% |
342.84 |
381.59 |
10.15% |
Does not meet 30 month clock |
10 |
|
Eplerenone |
Oral |
Tablet 25 mg |
71.75 |
11.09% |
63.79 |
71.75 |
11.09% |
Does not meet 30 month clock |
10 |
|
Eplerenone |
Oral |
Tablet 50 mg |
71.75 |
11.09% |
63.79 |
71.75 |
11.09% |
Does not meet 30 month clock |
10 |
|
Frusemide |
Injection |
Injection 20 mg in 2 mL |
2.00 |
38.74% |
1.23 |
2.00 |
38.50% |
OWAPD |
30 |
|
Imatinib |
Oral |
Capsule 100 mg (as mesilate) |
1,168.50 |
27.15% |
851.25 |
1,168.50 |
27.15% |
Does not meet 30 month clock |
10 |
|
Imatinib |
Oral |
Capsule 400 mg (as mesilate) |
2,337.00 |
27.15% |
1,702.50 |
2,337.00 |
27.15% |
Does not meet 30 month clock |
10 |
|
Imatinib |
Oral |
Tablet 100 mg (as mesilate) |
1,168.50 |
27.15% |
851.25 |
1,168.50 |
27.15% |
Does not meet 30 month clock |
10 |
|
Imatinib |
Oral |
Tablet 400 mg (as mesilate) |
2,337.00 |
27.15% |
1,702.50 |
2,337.00 |
27.15% |
Does not meet 30 month clock |
10 |
|
Infliximab |
Injection |
Powder for I.V. infusion 100 mg |
507.42 |
11.59% |
448.61 |
507.42 |
11.59% |
Does not meet 30 month clock |
10 |
|
Modafinil |
Oral |
Tablet 100 mg |
126.00 |
13.53% |
108.95 |
126.00 |
13.53% |
Does not meet 30 month clock |
10 |
|
Nevirapine |
Oral |
Tablet 200 mg |
157.14 |
34.88% |
102.33 |
157.14 |
34.88% |
GWAPD |
30 |
|
Nevirapine |
Oral |
Tablet 400 mg (extended release) |
157.14 |
34.88% |
102.33 |
157.14 |
34.88% |
GWAPD |
30 |
|
Nicorandil |
Oral |
Tablets 10 mg, 60 |
13.00 |
26.82% |
9.51 |
13.00 |
26.85% |
GWAPD |
10 |
|
Nicorandil |
Oral |
Tablets 20 mg, 60 |
18.11 |
26.82% |
13.25 |
18.11 |
26.84% |
GWAPD |
10 |
|
Oxycodone* |
Oral |
Tablet containing oxycodone hydrochloride 10 mg (controlled release) |
12.21 |
16.21% |
10.23 |
12.21 |
16.22% |
GWAPD |
10 |
|
Oxycodone* |
Oral |
Tablet containing oxycodone hydrochloride 20 mg (controlled release) |
21.63 |
16.21% |
18.12 |
21.63 |
16.23% |
GWAPD |
10 |
|
Oxycodone* |
Oral |
Tablet containing oxycodone hydrochloride 40 mg (controlled release) |
37.98 |
16.21% |
31.82 |
37.98 |
16.22% |
GWAPD |
10 |
|
Oxycodone* |
Oral |
Tablet containing oxycodone hydrochloride 5 mg |
2.16 |
16.21% |
1.81 |
2.16 |
16.20% |
GWAPD |
10 |
|
Oxycodone* |
Oral |
Tablet containing oxycodone hydrochloride 80 mg (controlled release) |
62.21 |
16.21% |
52.13 |
62.21 |
16.20% |
GWAPD |
10 |
|
Pemetrexed |
Injection |
Powder for I.V. infusion 1 g (as disodium) |
208.08 |
55.58% |
92.43 |
131.35 |
29.63% |
Does not meet 30 month clock |
10 |
|
Pemetrexed |
Injection |
Powder for I.V. infusion 100 mg (as disodium) |
20.81 |
55.58% |
9.24 |
13.14 |
29.68% |
Does not meet 30 month clock |
10 |
|
Pemetrexed |
Injection |
Powder for I.V. infusion 500 mg (as disodium) |
104.04 |
55.58% |
46.21 |
65.67 |
29.63% |
Does not meet 30 month clock |
10 |
|
Pregabalin |
Oral |
Capsule 150 mg |
41.96 |
25.00% |
31.47 |
40.82 |
22.91% |
Does not meet 30 month clock |
10 |
|
Pregabalin |
Oral |
Capsule 25 mg |
12.36 |
25.00% |
9.27 |
12.03 |
22.94% |
Does not meet 30 month clock |
10 |
|
Pregabalin |
Oral |
Capsule 300 mg |
62.60 |
25.00% |
46.95 |
60.91 |
22.92% |
Does not meet 30 month clock |
10 |
|
Pregabalin |
Oral |
Capsule 75 mg |
27.35 |
25.00% |
20.51 |
26.61 |
22.92% |
Does not meet 30 month clock |
10 |
|
Raloxifene |
Oral |
Tablet containing raloxifene hydrochloride 60 mg |
31.40 |
12.91% |
27.35 |
31.40 |
12.90% |
GWAPD |
10 |
|
Tirofiban |
Injection |
Solution concentrate for I.V. infusion 12.5 mg (as hydrochloride) in 50 mL |
203.27 |
10.22% |
182.50 |
203.27 |
10.22% |
GWAPD |
10 |
|
Tranexamic acid |
Oral |
Tablet 500 mg |
30.25 |
10.27% |
27.14 |
30.25 |
10.28% |
Does not meet 30 month clock |
10 |
|
Ursodeoxycholic acid* |
Oral |
Capsule 250 mg |
136.00 |
28.58% |
97.13 |
136.00 |
28.58% |
GWAPD |
10 |
|
Valganciclovir |
Oral |
Tablet 450 mg (as hydrochloride) |
1,792.15 |
15.95% |
1,506.30 |
1,792.15 |
15.95% |
Does not meet 30 month clock |
10 |
|
Valsartan with hydrochlorothiazide |
Oral |
Tablet 160 mg-12.5 mg |
12.04 |
28.55% |
8.60 |
9.95 |
13.57% |
GWAPD |
10 |
|
Valsartan with hydrochlorothiazide |
Oral |
Tablet 160 mg-25 mg |
13.45 |
28.55% |
9.61 |
11.36 |
15.40% |
GWAPD |
10 |
|
Valsartan with hydrochlorothiazide |
Oral |
Tablet 320 mg-12.5 mg |
15.04 |
28.55% |
10.75 |
12.36 |
13.03% |
GWAPD |
10 |
|
Valsartan with hydrochlorothiazide |
Oral |
Tablet 320 mg-25 mg |
16.45 |
28.55% |
11.75 |
13.77 |
14.67% |
GWAPD |
10 |
|
Valsartan with hydrochlorothiazide |
Oral |
Tablet 80 mg-12.5 mg |
9.69 |
28.55% |
6.92 |
8.06 |
14.14% |
GWAPD |
10 |
